BioAtla (BCAB) Long-Term Deferred Tax (2024 - 2025)
BioAtla (BCAB) posted quarterly Long-Term Deferred Tax of $51.5 million for Q4 2025, up 28021.86% year-over-year from N/an in Q4 2024, and up 28021.86% quarter-over-quarter from $183000.0 in Q4 2024.
BioAtla (BCAB) Long-Term Deferred Tax (2024 - 2025) Analysis & Trends
BioAtla's Long-Term Deferred Tax history runs 2 years deep, the most recent figure standing at $51.5 million for Q4 2025.
- In Q4 2025, Long-Term Deferred Tax rose 28021.86% year-over-year to $51.5 million; the TTM figure through Dec 2025 stood at $51.5 million (up 28021.86% YoY), while the FY2025 annual figure was $51.5 million, up 28021.86% from the prior year.
- Long-Term Deferred Tax for Q4 2025 stood at $51.5 million, up from $183000.0 in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $51.5 million in Q4 2025, with the low at $183000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | BioAtla | 5.41 Mn | 5.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 51.46 Mn |
| Dec 31, 2024 | 183,000.00 |